GRDN
Guardian Pharmacy Services, Inc.
GRDN's outlook is improving, though it still trails on the overall score.
LLY
Eli Lilly and Company
LLY has the edge over GRDN overall, supported by stronger fundamentals and stronger valuation.
GRDN Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Strong |
GRDN's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
GRDN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 34x | $49.38 | — |
| Current | 42x | $49.38 | — |
| Cheap | 44x | $51.74 | +4.8% |
| Fair | 48x | $56.09 | +14% |
| Expensive | 51x | $59.75 | +21% |
Historical ranges are pointers, not guarantees.
GRDN has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
GRDN Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for GRDN, with profitability improving.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
GRDN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.47 | +25% |
| Q3 2026 | $1.17 | +83% |
| Q2 2026 | $1.03 | +$2.54 |
| Q1 2026 | $0.83 | +$2.31 |
| Q4 2025 | $0.77 | +$2.54 |
| Q3 2025 | $0.64 | +$2.23 |
| Q2 2025 | -$1.51 | -786% |
| Q1 2025 | -$1.48 | -470% |
| Q4 2024 | -$1.77 | -411% |
GRDN earned $1.17 per share over the past year, up 83% from the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over GRDN on earnings, with more consistent year-over-year improvement.
GRDN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $371.1M | -1.7% |
| Q2 2026 | $351.8M | +2.2% |
| Q1 2026 | $336.6M | +2.2% |
| Q4 2025 | $397.6M | +17% |
| Q3 2025 | $377.4M | +20% |
| Q2 2025 | $344.3M | +15% |
| Q1 2025 | $329.3M | +20% |
| Q4 2024 | $338.6M | +20% |
GRDN's revenue is growing: $371M last quarter, down 1.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 6.8% | +2.3 points |
| Q2 2026 | 5.9% | +2.2 points |
| Q1 2026 | 5.3% | +1.3 points |
| Q4 2025 | 9.2% | +4.2 points |
| Q3 2025 | 4.5% | +38 points |
| Q2 2025 | 3.6% | -2 points |
| Q1 2025 | 4% | +1.1 points |
| Q4 2024 | 5% | -0.6 points |
GRDN's operating margin was 6.8% last quarter, up 2.3 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over GRDN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over GRDN on profitability, with a higher operating margin.
GRDN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $43.4M | +89% |
| Q2 2026 | $25.4M | +63% |
| Q1 2026 | $1M | -91% |
| Q4 2025 | $30.4M | +70% |
| Q3 2025 | $23M | +$30.3M |
| Q2 2025 | $15.6M | -40% |
| Q1 2025 | $11.7M | +137% |
| Q4 2024 | $17.8M | +51% |
GRDN generated $100M in free cash flow over the past year, up 47% from the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
GRDN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +80K shares |
| 1 year | +0.8% | +484K shares |
| 3 years | +5% | +3.1M shares |
| 5 years | +5% | +3.1M shares |
| Available history | +5% | +3.1M shares |
GRDN has 64M diluted shares, up 0.8% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | $30.3M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $29M |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over GRDN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
GRDN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.9x | Net Cash |
| Q2 2026 | -0.5x | Net Cash |
| Q1 2026 | -0.3x | Net Cash |
| Q4 2025 | -0.3x | Net Cash |
| Q3 2025 | -0.0x | Net Cash |
| Q2 2024 | 1.4x | Healthy |
| Q1 2024 | -0.0x | Net Cash |
| Q4 2023 | 1.2x | Healthy |
GRDN has the edge over LLY on leverage, with a lower net debt burden relative to earnings.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
GRDN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 67.4 | Neutral |
| Stochastic | 60.9 | Neutral |
GRDN's weekly RSI is 67 (neutral) and its Stochastic is 61 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
GRDN PE vs Healthcare Sector
| Metric | GRDN | Sector median | Relative |
|---|---|---|---|
| PE | 42x | 26x | 63% above |
| PE % | 8 | 59 | 51 pts below |
GRDN has the edge over LLY on valuation relative to its sector.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
GRDN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $42.0 | 17% above |
| 20 week MA | $41.3 | 20% above |
| 50 week MA | $37.5 | 32% above |
| 100 week MA | $30.3 | 63% above |
LLY has stronger trend alignment. GRDN is above 4 of 4 weekly averages versus LLY above 5 of 5.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
GRDN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $17.8 | $21.2 | +19% |
| 2025 | $21.2 | $30.7 | +45% |
| 2026 YTD | $30.7 | $49.4 | +61% |
GRDN has the edge over LLY on returns for 2026, with the stronger performance.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.